Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Sees Significant Growth in Short Interest

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) saw a significant increase in short interest during the month of August. As of August 15th, there was short interest totalling 1,620,000 shares, an increase of 51.4% from the July 31st total of 1,070,000 shares. Based on an average trading volume of 559,700 shares, the days-to-cover ratio is presently 2.9 days.

Wall Street Analyst Weigh In

Several brokerages have weighed in on BCLI. StockNews.com started coverage on Brainstorm Cell Therapeutics in a report on Friday. They issued a “hold” rating for the company. Maxim Group raised shares of Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a research note on Thursday, July 11th.

Brainstorm Cell Therapeutics Stock Performance

BCLI traded down $0.01 during trading on Friday, reaching $0.31. The company had a trading volume of 153,157 shares, compared to its average volume of 773,518. Brainstorm Cell Therapeutics has a 12-month low of $0.13 and a 12-month high of $1.79. The firm’s 50-day simple moving average is $0.34 and its 200 day simple moving average is $0.43. The company has a market cap of $21.66 million, a price-to-earnings ratio of -1.00 and a beta of 0.37.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). During the same quarter last year, the firm earned ($0.27) EPS. On average, sell-side analysts expect that Brainstorm Cell Therapeutics will post -0.14 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics as of its most recent SEC filing. 14.33% of the stock is currently owned by institutional investors and hedge funds.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.